AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Leigh Syndrome

Recent research efforts aimed at curing Leigh Syndrome.

Last updated

Leigh Syndrome

Overview

Leigh syndrome, also called Leigh syndrome spectrum, is a rare inherited disorder in which mitochondria—the cell structures that make usable energy—cannot meet the high energy demands of the brain and other organs. It usually begins in infancy or early childhood with developmental delay or loss of skills, abnormal movement, feeding problems, seizures, breathing abnormalities, and characteristic injury to deep brain structures on MRI; causes may lie in either nuclear DNA or mitochondrial DNA. GeneReviews: Nuclear Gene-Encoded Leigh Syndrome Spectrum (ncbi.nlm.nih.gov)

Outcomes differ greatly by the underlying gene, age at onset, and involvement of the brainstem, heart, or respiratory system, but early-onset disease is often severe and progressive; GeneReviews notes that up to half of people with nuclear-gene Leigh syndrome spectrum die by age three years. GeneReviews: Nuclear Gene-Encoded Leigh Syndrome Spectrum (ncbi.nlm.nih.gov) There is no approved curative treatment. Current care is multidisciplinary and supportive—managing acidosis, seizures, movement symptoms, nutrition, breathing, heart disease, rehabilitation, and complications—while genetic diagnosis can identify the minority of causes for which a mechanism-specific treatment may help. GeneReviews: mtDNA-Associated Leigh Syndrome Spectrum (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has become more targeted and more translational: investigators are testing gene replacement for single-gene nuclear forms, searching for medicines that improve mitochondrial redox balance or energy metabolism across several genetic forms, and building patient registries and natural-history studies needed for practical clinical trials. Leigh syndrome global patient registry (pmc.ncbi.nlm.nih.gov) The field is active but remains far from a universal cure because Leigh syndrome is a genetically diverse group of disorders rather than one molecular disease; the most plausible curative path currently is personalized treatment for defined genetic subtypes, especially nuclear-gene deficiencies amenable to gene replacement. Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Gene replacement for nuclear-gene forms is the clearest potentially curative strategy in preclinical development. In a 2020 study, intravenous delivery of a brain-penetrating adeno-associated virus (AAV) carrying a working NDUFS4 gene restored complex I activity in several organs, improved behavior and metabolic measures, reduced pathology in brain, retina, and heart, and extended survival in an adult mouse model. Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov) This was an important proof of principle because it showed that a treatment may need to reach both the nervous system and peripheral organs rather than the brain alone. Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov)

A parallel program targets SURF1-related Leigh syndrome, a complex IV deficiency. An intrathecal AAV9-SURF1 construct partly restored complex IV activity in brain, liver, and muscle and improved exercise-induced lactic acidosis in Surf1-deficient mice after a single dose. AAV9 gene replacement for SURF1 Leigh syndrome (pubmed.ncbi.nlm.nih.gov) Importantly, a 2025 follow-up found toxicity in dorsal-root-ganglion and heart tissue from the original high-expression construct in rats; redesigning the promoter and regulatory sequence lowered SURF1 expression while retaining efficacy signals and minimizing toxicity in rodents. Improved AAV9-SURF1 design (pubmed.ncbi.nlm.nih.gov) This is progress toward a clinically usable vector, but it also demonstrates why preclinical safety work is indispensable before first-in-human dosing. Improved AAV9-SURF1 design (pubmed.ncbi.nlm.nih.gov)

Metabolic and redox-directed approaches seek to protect cells despite the underlying mutation rather than replace the defective gene. In Ndufs4 knockout mice, continuous exposure to 11% oxygen prevented neurodegeneration and increased lifespan by about fivefold; investigators linked benefit to correction of abnormally high brain oxygen exposure and preservation of NAD+, an essential cellular electron carrier. Hypoxia and NAD+ in Leigh mice (pubmed.ncbi.nlm.nih.gov) Hypoxia is not an established human treatment and would require exceptionally careful safety testing, but the work identifies oxygen handling and NAD+ balance as actionable disease mechanisms. Hypoxia and NAD+ in Leigh mice (pubmed.ncbi.nlm.nih.gov)

Human-cell drug discovery has accelerated substantially. In 2026, researchers combined patient-derived SURF1 brain organoids, single-cell RNA sequencing, deep-learning drug-repurposing predictions, and a yeast survival screen; both screening routes converged on azole compounds, and talarozole and sertaconazole improved neuronal structure, lactate release, and growth in Leigh midbrain organoids. Deep-learning screening in brain organoids (doi.org) These are laboratory results, not evidence that either drug works in people with Leigh syndrome, but they provide specific repurposing candidates and a repeatable platform for precision drug discovery. Deep-learning screening in brain organoids (doi.org)

Clinical Trials and Experimental Approaches

The most directly Leigh-focused current interventional program identified in public records is Thiogenesis Therapeutics’ registered Phase 2a study of oral TTI-0102, a cysteamine-derived compound intended to improve thiol/redox balance. The study is designed as a sequential dose-ranging trial in adolescents, adults, and children with Leigh syndrome spectrum; the ClinicalTrials.gov record was listed as not yet recruiting in its latest publicly surfaced update, while the sponsor reports that the FDA-cleared trial is planned to begin in 2026. TTI-0102 Phase 2a trial, NCT06990984 (clinicaltrials.gov) No Leigh-specific efficacy results have been posted. TTI-0102 Phase 2a trial, NCT06990984 (clinicaltrials.gov)

Vatiquinone, formerly EPI-743/PTC-743, has been studied across inherited mitochondrial diseases, including earlier Leigh syndrome studies. Its later open-label safety study, NCT05218655, enrolled 101 previously treated participants with inherited mitochondrial disease but was terminated early after PTC discontinued development for that indication based on prior study results; therefore it does not currently provide evidence of a disease-modifying benefit in Leigh syndrome. Vatiquinone long-term safety study, NCT05218655 (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers use complementary models because no single model captures every form of Leigh syndrome. These include genetically engineered mice such as Ndufs4 and Surf1 knockouts; patient fibroblasts; induced pluripotent stem cells—adult cells reprogrammed into stem cells—and brain organoids; and yeast models for high-throughput survival screens. Improved AAV9-SURF1 design (pubmed.ncbi.nlm.nih.gov) Deep-learning screening in brain organoids (doi.org)

The principal measurements are equally broad: mitochondrial respiratory-chain activity, lactate and acid-base markers, neuroimaging, movement and behavioral outcomes, survival, cell-type-specific gene-expression changes, and patient- or caregiver-reported disease burden. Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov) A global registry begun in 2021 and the Leigh Syndrome International Consortium’s prospective natural-history study are intended to turn these observations into validated clinical-trial endpoints and to make recruitment more feasible for such a rare, genetically heterogeneous condition. Leigh syndrome global patient registry (pmc.ncbi.nlm.nih.gov) LSIC Natural History Study (leighsyndrome.org)

Leading Institutions and Funding

Notable academic contributors include UT Southwestern Medical Center and UMass Chan Medical School in SURF1 AAV development, and the Grenoble/EPFL/Telethon Institute of Genetics and Medicine collaboration behind NDUFS4 gene replacement. Improved AAV9-SURF1 design (pubmed.ncbi.nlm.nih.gov) Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov) The 2026 organoid-screening work involves European mitochondrial-disease and stem-cell research groups and illustrates the growing role of computational biology alongside traditional mitochondrial laboratories. Deep-learning screening in brain organoids (doi.org)

Patient-led organizations are unusually important in this field. The Leigh Syndrome International Consortium—formed by the Lily Foundation, Mitocon, Mito Foundation, UMDF, and People Against Leigh Syndrome—reports commitments of more than US$1 million to its multi-year research effort. Leigh Syndrome International Consortium (leighsyndrome.org) Cure Mito Foundation received a five-year, US$800,000 Chan Zuckerberg Initiative Rare As One capacity-building grant in 2024 and supports disease models, gene therapy, drug repurposing, and a global registry. Patient-led advocacy and research expansion (pmc.ncbi.nlm.nih.gov)

Strengths, Limitations, and Challenges

The major strength of the current landscape is that it now contains therapies matched to biology: gene replacement for loss-of-function nuclear genes, pathway-directed medicines for shared metabolic stress, and human organoid systems that can test drugs in disease-relevant neural cells. AAV9 gene replacement for SURF1 Leigh syndrome (pubmed.ncbi.nlm.nih.gov) Deep-learning screening in brain organoids (doi.org) The registry and natural-history infrastructure also address a central rare-disease problem: small, dispersed patient populations and limited knowledge of which outcome measures change reliably over time. Leigh syndrome global patient registry (pmc.ncbi.nlm.nih.gov)

The limitations are substantial. AAV gene replacement is relevant only to selected nuclear-gene causes and must safely reach the brain and often multiple peripheral organs; the revised SURF1 vector’s rodent toxicity findings show that excessive transgene expression can itself be harmful. Improved AAV9-SURF1 design (pubmed.ncbi.nlm.nih.gov) Broad metabolic therapies may be easier to deploy across genotypes but may reduce symptoms or slow injury rather than correct the causal mutation, and promising results in mice or organoids cannot establish clinical benefit. Hypoxia and NAD+ in Leigh mice (pubmed.ncbi.nlm.nih.gov) Deep-learning screening in brain organoids (doi.org)

Outlook and Future Directions

As of October 21, 2026, a cure for Leigh syndrome is not near for the syndrome as a whole, but subtype-specific cures are becoming scientifically credible—most notably gene replacement for carefully selected nuclear-gene defects. Gene replacement in Ndufs4 mice (pubmed.ncbi.nlm.nih.gov) The milestones to watch are first-in-human testing of optimized gene-replacement vectors, results from the TTI-0102 Phase 2a program, independent validation of organoid-screened drug candidates, and completion of prospective natural-history datasets that can support adequately designed trials. TTI-0102 Phase 2a trial, NCT06990984 (clinicaltrials.gov) LSIC Natural History Study (leighsyndrome.org)

References

Don't see your disease? Request a report